Literature DB >> 7475273

Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.

G M Marshall1, E Kwan, M Haber, M J Brisco, P J Sykes, A A Morley, I Toogood, K Waters, G Tauro, H Ekert.   

Abstract

Instability of antigen receptor gene rearrangements during progression of acute lymphoblastic leukemia (ALL) has important implications for polymerase chain reaction (PCR)-based techniques using these genes for the detection of minimal residual disease (MRD). Antigen receptor gene instability may lead to false negative results in bone marrow samples taken during remission. Utilizing the PCR and consensus primers for rearranged immunoglobulin heavy chain (IgH) and T cell receptor gamma (TCR gamma) gene sequences, we analyzed the bone marrow samples at diagnosis and first relapse for 37 children with ALL. The incidence of clonal evolution at the IgH locus was 9/33 (27%) and at the TCR gamma locus 1/15 (7%). In four of the nine patients with clonal evolution at the IgH locus, the sequence at relapse retained the diversity and joining region (D-N-J) sequences from diagnosis. Patients with clonal evolution were characterized by a higher incidence of more than one IgH PCR band at diagnosis and by late relapse (> 18 months from diagnosis). These results suggest that, where possible, patients with more than one IgH PCR rearrangement at diagnosis should be monitored using another antigen receptor gene, such as TCR gamma, since evolution for this gene was found to be a rare event. By combining this approach with a strategy directed at the more stable D-N-J region of the IgH gene, MRD false negativity would have occurred in less than 10% of patients in the present study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475273

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

Review 1.  The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies.

Authors:  Anna Gazzola; Claudia Mannu; Maura Rossi; Maria Antonella Laginestra; Maria Rosaria Sapienza; Fabio Fuligni; Maryam Etebari; Federica Melle; Elena Sabattini; Claudio Agostinelli; Francesco Bacci; Carlo Alberto Sagramoso Sacchetti; Stefano Aldo Pileri; Pier Paolo Piccaluga
Journal:  Ther Adv Hematol       Date:  2014-04

2.  Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.

Authors:  Charles Gawad; Francois Pepin; Victoria E H Carlton; Mark Klinger; Aaron C Logan; David B Miklos; Malek Faham; Gary Dahl; Norman Lacayo
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

3.  Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.

Authors:  A Lal; E Kwan; M al Mahr; L Zhou; D Ferrara; V Tobias; D O'Gorman Hughes; M Haber; M D Norris; G M Marshall
Journal:  Mol Pathol       Date:  1998-10

4.  Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Authors:  Michael J Brisco; Sue Latham; Rosemary Sutton; Elizabeth Hughes; Vicki Wilczek; Katrina van Zanten; Bradley Budgen; Anita Y Bahar; Maria Malec; Pamela J Sykes; Bryone J Kuss; Keith Waters; Nicola C Venn; Jodie E Giles; Michelle Haber; Murray D Norris; Glenn M Marshall; Alexander A Morley
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

5.  Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Letha A Phillips; Xiaoping Su; Jing Ma; Christopher B Miller; Sheila A Shurtleff; James R Downing
Journal:  Science       Date:  2008-11-28       Impact factor: 47.728

6.  Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Babasaheb D Yadav; Amy L Samuels; Julia E Wells; Rosemary Sutton; Nicola C Venn; Katerina Bendak; Denise Anderson; Glenn M Marshall; Catherine H Cole; Alex H Beesley; Ursula R Kees; Richard B Lock
Journal:  Oncotarget       Date:  2016-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.